Robert W. Baird Issues Positive Forecast for Denali Therapeutics (NASDAQ:DNLI) Stock Price

Denali Therapeutics (NASDAQ:DNLI) had its price target boosted by Robert W. Baird from $29.00 to $32.00 in a research report released on Thursday,Benzinga reports. Robert W. Baird currently has an outperform rating on the stock.

Several other analysts also recently commented on DNLI. UBS Group assumed coverage on shares of Denali Therapeutics in a research report on Wednesday, January 7th. They set a “buy” rating on the stock. Wolfe Research assumed coverage on shares of Denali Therapeutics in a report on Monday, February 23rd. They issued a “peer perform” rating for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Denali Therapeutics in a research note on Wednesday, January 21st. Jefferies Financial Group reiterated a “buy” rating and set a $40.00 price target on shares of Denali Therapeutics in a report on Monday, March 2nd. Finally, BTIG Research raised their price target on shares of Denali Therapeutics from $32.00 to $36.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Denali Therapeutics has an average rating of “Moderate Buy” and an average price target of $34.82.

Denali Therapeutics Trading Down 12.1%

Denali Therapeutics stock opened at $19.74 on Thursday. The company has a current ratio of 9.16, a quick ratio of 9.16 and a debt-to-equity ratio of 0.01. The business’s fifty day simple moving average is $20.43 and its two-hundred day simple moving average is $17.81. Denali Therapeutics has a 12 month low of $10.57 and a 12 month high of $23.77. The company has a market capitalization of $3.13 billion, a price-to-earnings ratio of -6.65 and a beta of 1.02.

Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($0.73) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.02. During the same period in the prior year, the company earned ($0.67) EPS. As a group, equities analysts predict that Denali Therapeutics will post -2.71 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Ryan J. Watts sold 35,198 shares of the stock in a transaction that occurred on Tuesday, January 6th. The shares were sold at an average price of $16.50, for a total transaction of $580,767.00. Following the transaction, the chief executive officer owned 296,833 shares in the company, valued at $4,897,744.50. This represents a 10.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Alexander O. Schuth sold 17,218 shares of the firm’s stock in a transaction that occurred on Tuesday, January 6th. The stock was sold at an average price of $16.50, for a total transaction of $284,097.00. Following the completion of the sale, the insider owned 282,828 shares in the company, valued at $4,666,662. This represents a 5.74% decrease in their position. The SEC filing for this sale provides additional information. 12.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Denali Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Foresite Capital Management VI LLC purchased a new stake in Denali Therapeutics in the third quarter worth about $14,520,000. AlphaQuest LLC grew its stake in shares of Denali Therapeutics by 224.1% during the 3rd quarter. AlphaQuest LLC now owns 74,422 shares of the company’s stock valued at $1,081,000 after acquiring an additional 51,458 shares during the period. Aberdeen Group plc grew its stake in shares of Denali Therapeutics by 23.4% during the 3rd quarter. Aberdeen Group plc now owns 1,113,586 shares of the company’s stock valued at $16,169,000 after acquiring an additional 210,835 shares during the period. Principal Financial Group Inc. grew its stake in shares of Denali Therapeutics by 18.5% during the 3rd quarter. Principal Financial Group Inc. now owns 1,271,190 shares of the company’s stock valued at $18,458,000 after acquiring an additional 198,207 shares during the period. Finally, Holocene Advisors LP increased its holdings in Denali Therapeutics by 677.8% in the 3rd quarter. Holocene Advisors LP now owns 3,135,712 shares of the company’s stock worth $45,531,000 after acquiring an additional 2,732,540 shares in the last quarter. 92.92% of the stock is owned by institutional investors.

More Denali Therapeutics News

Here are the key news stories impacting Denali Therapeutics this week:

• Positive Sentiment: FDA accelerated approval of AVLAYAH (tividenofusp alfa‑eknm), Denali’s first commercial drug and the first transferrin‑receptor (brain‑penetrant) biologic for Hunter syndrome; approval includes a Rare Pediatric Disease PRV and Denali is launching U.S. commercialization and patient support services. GlobeNewswire: DNLI FDA Approval Zacks: Denali Wins FDA Nod
• Positive Sentiment: Multiple brokerages boosted price targets and ratings today (Morgan Stanley to $42/overweight; Goldman Sachs to $40/buy; Stifel to $41/buy; BTIG, HC Wainwright, Baird also raised targets), signaling strong analyst conviction about AVLAYAH’s commercial and platform upside. Benzinga: Analyst Coverage Roundup
• Neutral Sentiment: Management hosted/announced a conference call and webcast to discuss approval and launch plans; an investor webcast and Seeking Alpha transcript provide additional color on commercialization timing, pricing strategy and the COMPASS confirmatory trial. Seeking Alpha: AVLAYAH Launch Transcript
• Negative Sentiment: The FDA approval is accelerated and based on a biomarker (CSF heparan sulfate); continued approval may be contingent on confirmatory Phase 2/3 COMPASS trial results — this creates execution and regulatory risk that could weigh on the stock if confirmatory data are delayed or mixed. GlobeNewswire: Approval Details & Risks
• Negative Sentiment: Reports show recent insider sales and significant institutional portfolio moves (large reductions by some funds reported), which can create near‑term supply pressure and headline risk despite the approval. QuiverQuant: Insider & Institutional Activity

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.